21148 ⎘
Medicinal preparations containing antigens or antibodies; Antibodies ; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
Anti-sclerostin antibody, antigen binding fragment and medical use thereof
#302Antibodies directed against interleukin 36 receptor (IL-36R)
#303THERAPEUTICS AND METHODS OF TREATING FIBROPROLIFERATIVE DISEASES
#304Single domain antibodies that bind to human CD20
#305Intranasal administration of guanidinylated aminoglycosides
#306Stable aqueous formulations of adalimumab
#307Stable aqueous formulations of adalimumab
#308Heterocyclic compounds and uses thereof
#309METHOD OF TREATING PRIMARY SCLEROSING CHOLANGITIS
#310Stable aqueous formulations of adalimumab
#311Stable aqueous formulations of adalimumab
#312COMPOUNDS FOR IMPROVING THE HALF-LIFE OF VON WILLEBRAND FACTOR
#313Methods for treating refractory anemia with ringed sideroblasts
#314Use of inhibitors of Bruton's tyrosine kinase (Btk)
#315Stable Aqueous Formulations of Adalimumab
#316Stable Aqueous Formulations of Adalimumab
#317Stable Aqueous Formulations of Adalimumab
#318Methods of manufacturing stable aqueous formulations of adalimumab
#319Syringe containing stable aqueous formulations of adalimumab
#320Use of toll-like receptor agonist for treating cancer
#321Stable aqueous formulations of adalimumab
#322Anticancer agents or antimetastatic agents using FSTL1 and combination drug thereof
#323Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#324Subcutaneously administered anti-IL-6 receptor antibody for treatment of juvenile idiopathic arthritis
#325Treatment of neonatal hypoxia including impairments or effects thereof
#326Envenomation therapies and related pharmaceutical compositions, systems and kits
#327Stuffing box loosening device and method
#328Anti-pro/latent-myostatin antibodies and uses thereof
#329Stable aqueous formulations of adalimumab
#330RSPO BINDING AGENTS AND USES THEREOF
#331A METHOD OF TREATING JOINT DISEASE
#332H3.3 CTL peptides and uses thereof
#333Compositions and methods for treating or preventing lupus
#334Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
#335Serum albumin binding proteins containing immunoglobulin single variable domains
#336Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
#337Compositions and methods for treating Crohn's disease and related conditions and infections
#338RSPO3 Binding Agents and Uses Thereof
#339POLYNUCLEOTIDES AND POLYPEPTIDE SEQUENCES INVOLVED IN THE PROCESS OF BONE REMODELING
#340Methods for treating osteogenesis imperfecta
#341Selective removal of age-modified cells for treatment of atherosclerosis
#342ANTI-INFLAMMATORY TREATMENT VIA INHIBITION OF ENDOTHELIAL CELL KINESIN LIGHT CHAIN 1, VARIANT 1 (KLC1C)
#343Methods for treating cancer
#344FORMULATIONS WITH REDUCED OXIDATION
#345BSL2v2c2-Ig polypeptides
#346Use of 15 male fertility related proteins or combination thereof
#347Compositions and Methods of Preventing Erythropoietin Associated Hypertension
#348Methods of treating a kit-associated cancer by administering anti-kit antibodies
#349Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier
#350HMG1 Antibody For Treating Inflammatory Conditions
#351Compositions and methods for inhibiting arginase activity
#352COMPOSITIONS COMPRISING ANTI-CD38 ANTIBODIES AND CARFILZOMIB
#353Pharmaceutical compositions comprising an antibody which binds the human anti-Müllerian hormone receptor type II
#354Nucleic acids encoding activatable antibodies that bind epidermal growth factor receptor
#355METHODS FOR TREATING RELAPSING FORMS OF MULTIPLE SCLEROSIS
#356Stable aqueous formulations of adalimumab
#357Lipid vesicle compositions and methods of use
#358Use of inhibitors of Bruton'S tyrosine kinase (Btk)
#359Anti-human PAI-1 antibody
#360Factor IX polypeptides and methods of use thereof
#361Isolated nucleotide sequences encoding GDF traps
#362Use of inhibitors of bruton's tyrosine kinase (BTK)
#363Polynucleotides encoding anti-kit antibodies
#364Stable aqueous formulations of adalimumab
#365Stable aqueous formulations of adalimumab
#366Stable aqueous formulations of adalimumab
#367Methods for reducing global chronic inflammation and the presence of melanoma
#368Stable aqueous formulations of adalimumab
#369Stable aqueous formulations of adalimumab
#370Stable aqueous formulations of adalimumab
#371Siglec-15 antibodies in treating bone loss-related disease
#372Stable aqueous formulations of adalimumab
#373Factor IX polypeptides and methods of use thereof
#374Stable aqueous formulations of adalimumab
#375Stable aqueous formulations of adalimumab
#376Stable aqueous formulations of adalimumab
#377Antibodies against phosphorylcholine in combination therapy with biologic agents
#378Phosphorylcholine in combination therapy with infliximab
#379Factor IX polypeptides and methods of use thereof
#380Compositions and methods for treatment of diabetic retinopathy
#381Antitumor agent and antitumor effect enhancer
#382Use of inhibitors of bruton's tyrosine kinase (Btk)
#383Factor IX polypeptides and methods of use thereof
#384Compositions including triciribine and trastuzumab and methods of use thereof
#385RSPO3 binding agents and uses thereof
#386Monoclonal antibodies to interleukin 35 and methods of use thereof to inhibit regulatory T cell function
#387Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C-C chemokine receptor 9 (CCR9) and anti-α4β7 integrin blocking antibodies
#388Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#389Treatment of Fibrodysplasia Ossificans Progressiva
#390Polynucleotides and polypeptide sequences involved in the process of bone remodeling
#391GENETICALLY MODIFIED HUMAN NATURAL KILLER CELL LINES
#392COMPOSITIONS AND METHODS FOR BINDING CYSTEINYL LEUKOTRIENES (CYSLTS) FOR TREATMENT OF DISEASE
#393Stable aqueous formulations of adalimumab
#394Method for Treating Eclampsia and Preeclampsia
#395Lipid vesicle compositions and methods of use
#396Stable aqueous formulations of adalimumab
#397Methods for treating osteogenesis imperfecta
#398Biomarker Hsp90 for predicting effect of a c-Met inhibitor
#399Method for treating muscle-invasive bladder cancer, containing S100A9 and EGFR inhibitors and cisplatin as active ingredients
#400Intranasal administration of guanidinylated aminoglycosides
#401Methods and compositions for the treatment and/or prevention of type 1 diabetes
#402Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
#403Anti-RSPO2 antibodies and uses thereof
#404CETUXIMAB WITH MODIFIED GLYCOSYLATION AND USES THEREOF
#405Notch inhibition in the prevention of vein graft failure
#406Human CGRP receptor binding proteins
#407Nucleic acids encoding rage fusion proteins
#408iPS/ES CELL-SPECIFIC ANTIBODY HAVING CYTOTOXICITY TO TARGET CELLS AND USE THEREOF
#409BTNL9 proteins, nucleic acids, and antibodies and uses thereof
#410Antibodies to IL-6 and use thereof
#411Pharmaceutical formulations
#412Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
#413Use of C-C Chemokine Receptor Type 7 (CCR7) Inhibitors
#414Amino acid sequences directed against cellular receptors for viruses and bacteria
#415Compositions and methods including a recombinant human MAB that promotes CNS remyelination
#416Antibodies against 6-sulfo-LacNac-positive human dendritic cells, and their use
#417Heterocyclic compounds and uses thereof
#418Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
#419Humanized anti-CD22 antibody
#420Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#421Methods for treating GI syndrome and graft versus host disease
#422Anti-Her3 scFV fragment and bispecific anti-c-Met/anti-Her3 antibodies comprising the same
#423METHOD TO IMPROVE PHARMACOKINETICS OF DRUGS
#424Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#425Anti-Tie2 antibodies and uses thereof
#426Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity
#427Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#428Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#429Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#430Anti-ETBR antibodies and immunoconjugates
#431Stable aqueous formulations of adalimumab
#432Stable aqueous formulations of adalimumab
#433Stable aqueous formulations of adalimumab
#434Stable aqueous formulations of adalimumab
#435Compositions and methods for diagnosing and treating cancer
#436Stable aqueous formulations of adalimumab
#437Compositions Comprising an Anti-PDGF Aptamer and a VEGF Antagonist
#438NOVEL THERAPEUTIC TREATMENTS WITH ANTI-HER2 ANTIBODIES HAVING A LOW FUCOSYLATION
#439Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
#440DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IMMUNE CELL RECEPTORS AND AUTOANTIGENS
#441Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
#442Methods and compositions for the treatment of cancer and infectious disease using alpha(2) macroglobulin-antigenic molecule complexes
#443Therapeutic combinations for treating Johne's disease
#444Methods of impairing osteoclast differentiation using antibodies that bind Siglec-15
#445DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF
#446Cancer therapy
#447FOXC1 ANTIBODIES AND METHODS OF THEIR USE
#448Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
#449P97 fragments with transfer activity
#450CDR-modified anti-Siglec-15 antibody
#451Nucleic acids encoding human antibodies to sialyl-lewis
#452Nucleic acids encoding anti-Siglec-15 antibodies
#453Treatment of Multiple Sclerosis With Anti-CD19 Antibody
#454Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
#455Bioconjugates of synthetic apelin polypeptides
#456Combination of kinase inhibitors and uses thereof
#457Monoclonal antibody against EL which inhibits enzyme activity of EL
#458Anti-RSPO2 antibodies
#459Anti-RSPO1 antibodies and uses thereof
#460Pharmaceutical compositions comprising an antibody which binds the human anti-mullerian hormone receptor type II
#461FUSION PROTEINS COMPRISING IGG2 HINGE DOMAINS
#462Pharmaceutical composition for a foaming eye drop
#463VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
#464Methods of generating hyper INOS expressing cells and uses thereof
#465Methods of administering immunosuppressants having a specified pharmacodynamic effective life and therapeutic macromolecules for the induction of immune tolerance
#466Methods comprising dosing combinations for reducing undesired humoral immune responses
#467Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
#468Tolerogenic synthetic nanocarriers to reduce or prevent anaphylaxis in response to a non-allergenic antigen
#469Peptide-mediated non-covalent delivery of active agents across the blood-brain barrier
#470Methods related to administering immunosuppressants and therapeutic macromolecules at a reduced pharmacodynamically effective dose
#471Pharmaceutical composition for the treatment of type-1 diabetes
#472Stimulation of ovarian follicle development and oocyte maturation
#473Isolated nucleotide sequences encoding GDF traps
#474Compositions including triciribine and trastuzumab and methods of use thereof
#475Antibacterial polymers and method for obtaining the same
#476RBM3 protein in colorectal cancer prognostics
#477SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS
#478Co-activation of mTOR and STAT3 pathways to promote neuronal survival and regeneration
#479Methods and compositions for modulation of blood-neural barrier
#480SUSTAINED DRUG DELIVERY SYSTEM
#481Use of Toll-Like Receptor agonist for treating cancer
#482Treatment of central nervous system disorders by intranasal administration of immunoglobulin G
#483Combination Treatments For Hepatitis C
#484LUNG CANCER BIOMARKERS
#485Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
#486Toll-like receptor 3 antagonists
#487SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR TREATMENT OF MEDICAL DISORDERS
#488Nucleic acid molecule encoding target antibodies directed to DLL4
#489Siglec-15 antibodies in treating bone loss-related disease
#490TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
#491Use of inhibitors of bruton's tyrosine kinase (BTK)
#492PROSTAGLANDIN E2 BINDING PROTEINS AND USES THEREOF
#493Anti-BAFFR antibody formulations
#494T-helper cell type 17 lineage-specific adjuvants, compositions and methods
#495RBM3 in bladder cancer
#496Methods of generating hyper iNOS expressing cells and uses thereof
#497Method for treating a GD2 positive cancer
#498Use of an anti-CD200 antibody for prolonging the survival of allografts
#499COMPOSITIONS FOR AMELIORATING SYSTEMIC INFLAMMATION AND METHODS FOR MAKING AND USING THEM
#500Polynucleotides encoding BSL2v2c2-Ig
#501Uses of NANOG inhibitors and related methods
#502COMPOSITION AND METHODS OF USE FOR BINDING MOLECULES TO DICKKOPF-1 OR DICKKOPF-4 OR BOTH
#503Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
#504Compositions and methods for treating or preventing lupus
#505Methods for inhibiting osteolysis
#506Anti-ceramide monoclonal antibody 2A2
#507Anti-FcRH5 antibodies and immunoconjugates and methods of use
#508Method and System for Treating Biological Tissue
#509Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists
#510Anti-kit antibodies
#511Methods for treating melanoma
#512Methods for reducing global chronic inflammation and the presence of melanoma
#513Subcutaneously administered anti-IL-6 receptor antibody
#514Subcutaneously administered anti-IL-6 receptor antibody for treatment of systemic sclerosis
#515SUBCUTANEOUSLY ADMINISTERED ANTI-IL-6 RECEPTOR ANTIBODY
#516Human antibodies and antibody-drug conjugates against CD74
#517RSPO3 binding agents and uses thereof
#518Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances
#519NOTCH inhibition in the treatment of cardiovascular disease
#520Highly concentrated anti-CD40 antibody pharmaceutical preparation
#521Stabilized formulations containing anti-DLL4 antibodies
#522Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
#523Compositions and methods including a recombinant human MAB that promotes CNS remyelination
#524Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
#525USE OF TRI-SUBSTITUTED GLYCEROL COMPOUNDS FOR THE TREATMENT OF HEMATOLOGICAL MALIGNANCIES
#526HUMAN GM-CSF ANTIGEN BINDING PROTEINS
#527Selective removal of age-modified cells for treatment of atherosclerosis
#528Methods for Treating Diseases and HSV Using Antibodies to Aminophospholipids
#529Methods and compositions for the inhibition of fructokinase
#530Antibodies to IL-6 to inhibit or treat inflammation
#531Anti-Tie2 antibodies and uses thereof
#532DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody
#533STEM CELL THERAPY USING INHIBITORS OF LYSOPHOSPHATIDIC ACID
#534Methods of treatment using rage fusion proteins
#535Factor IX polypeptides and methods of use thereof
#536HUMAN CYTOMEGALOVIRUS VACCINE
#537THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
#538Immunotherapeutic method involving CD123 (IL-3Rα) antibodies and immunostimulating complex
#539Antibodies which bind factor VIII
#540METHOD FOR PRESERVING FOOD
#541Treatment drug for autoimmune diseases and allergic diseases
#542BTNL9 PROTEINS, NUCLEIC ACIDS, AND ANTIBODIES AND USES THEREOF
#543Anti-RSPO1 antibodies
#544Anti-FcRH5 antibodies and immunoconjugates and methods of use
#545KIM-1 ANTIBODIES FOR TREATMENT OF TH2-MEDIATED CONDITIONS
#546Compositions including triciribine and trastuzumab and methods of use thereof
#547Cancer targets and uses thereof
#548Human CGRP Receptor Binding Proteins
#549LINGO binding molecules and Pharmaceutical Use Thereof
#550Pharmaceutical composition for treating and/or preventing cancer
#551Isolated nucleotide sequences encoding GDF traps
#552Methods for treatment of inflammatory diseases
#553COMBINATION THERAPY
#554P97 fragments with transfer activity
#555Genetically modified human natural killer cell lines
#556Siglec 15 antibodies in treating bone loss-related disease
#557HMG1 antibody for treating inflammatory conditions
#558Combination therapy with antibody-drug conjugates
#559Interleukin-31 monoclonal antibody
#560Antibodies Against Phosphorylcholine In Combination Therapy with Biologic Agents
#561Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells
#562Methods of using antibodies that bind the glutamate ligand binding region of Notch1
#563Actagardine derivatives, and pharmaceutical use thereof
#564Reagents and treatment methods for autoimmune diseases
#565Subcutaneously administered anti-IL-6 receptor antibody
#566Enhancement of the action of anti-infective agents and of central and peripheral nervous system agents and transportation of nucleic acid substances
#567Antibodies that bind polypeptides involved in the process of bone remodeling
#568Bi-specific digoxigenin binding antibodies
#569COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH AN ANTI-BCL-2 ACTIVE AGENT
#570Treatment of cancer
#571Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
#572VASCULAR ENDOTHELIAL CELL GROWTH FACTOR ANTAGONISTS AND USES THEREOF
#573SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE TREATMENT OF DEMYELINATING DISORDERS
#574FOXC1 ANTIBODIES AND METHODS OF THEIR USE
#575METHOD FOR TREATING MULTIPLE SCLEROSIS
#576Method of treating a malignant tumor by administering antibodies directed to DLL4
#577Use of inhibitors of bruton's tyrosine kinase (Btk)
#578Lipid vesicle compositions and methods of use
#579Methods and compositions for modulation of blood-neural barrier
#580Cyclophosphamide in combination with anti-idiotypic vaccines
#581Soluble tumor necrosis factor receptor treatment of medical disorders
#582NOTCH Inhibition in the Treatment or Prevention of Atherosclerosis
#583mTOR INHIBITOR AND ANGIOGENESIS INHIBITOR COMBINATION THERAPY
#584PEPTIDE-MEDIATED NON-COVALENT DELIVERY OF ACTIVE AGENTS ACROSS THE BLOOD-BRAIN BARRIER
#585Anti-KTPAF50 antibodies and their uses in therapeutic and diagnostic methods
#586THE USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
#587USE OF INHIBITORS OF BRUTON'S TYROSINE KINASE (BTK)
#588Methods for treating melanoma
#589Antibodies that bind tyrosyl-tRNA synthetases
#590Compositions and Methods for Preventing Erythropoietin-Associated Hypertension
#591Methods For Treating Diseases and HCV Using Antibodies To Aminophospholipids
#592COMPOSITIONS AND METHODS OF USE FOR BINDING MOLECULES TO DICKKOPF-1 OR DICKKOPF-4 OR BOTH
#593RBM3 in Testicular Cancer Diagnostics and Prognostics
#594T-helper cell type 17 lineage-specific adjuvants, compositions and methods
#595RBM3 in colorectal cancer prognostics
#596PREVENTION AND TREATMENT OF PAIN USING MONOCLONAL ANTIBODIES AND ANTIBODY FRAGMENTS TO LYSOPHOSPHATIDIC ACID
#597Amino acid sequences directed against cellular receptors for viruses and bacteria
#598Antibodies that bind polypeptides involved in the process of bone remodeling
#599Compounds
#600Polynucleotides encoding BSL2vcvc-lg